Learn benefits, uses, and who can benefit from this effective treatment
Co-IP and molecular docking identified protein interactions
The capsules are intended to be taken after occasions when alcohol has been consumed, following the dosage instructions provided
The pituitary TGF1 system as a novel target for the treatment of resistant prolactinomas
Applications Claiming Priority (4) Related Parent Applications (1) Publications (2) Family ID=43306962 Family Applications (2) Family Applications Before (1) Country Status (7) Cited By (2) Families Citing this family (24) Citations (3) Family Cites Families (73) 2010 2010-06-15 WO PCT/US2010/038642 patent/WO2010147962A1/en not_active Ceased 2010-06-15 EP EP20100790043 patent/EP2442645B1/en active Active 2010-06-15 ES ES14181820.3T patent/ES2579173T3/en active Active 2010-06-15 PL PL14181820T patent/PL2821405T3/en unknown 2010-06-15 DK DK14181820.3T patent/DK2821405T3/en active 2010-06-15 US US12/815,526 patent/US8410162B2/en active Active 2010-06-15 PT PT10790043T patent/PT2442645E/en unknown 2010-06-15 PT PT141818203T patent/PT2821405E/en unknown 2010-06-15 EP EP14181820.3A patent/EP2821405B1/en active Active 2010-06-15 ES ES10790043.3T patent/ES2524706T3/en active Active 2010-06-15 PL PL10790043T patent/PL2442645T3/en unknown 2010-06-15 DK DK10790043T patent/DK2442645T3/en active 2013 2013-03-27 US US13/851,355 patent/US20140121266A1/en not_active Abandoned 2014 2014-10-28 US US14/525,471 patent/US9326970B2/en active Active 2016 2016-04-05 US US15/091,389 patent/US20160287557A1/en not_active Abandoned 2017 2017-12-11 US US15/837,171 patent/US20180228767A1/en not_active Abandoned 2020 2020-02-14 US US16/791,265 patent/US20200352903A1/en not_active Abandoned 2022 2022-02-04 US US17/592,700 patent/US20220151988A1/en not_active Abandoned
